Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x5 intravenous administration

British Journal of Cancer

Volumn 73, Issue 6, 1996, Pages 744-750

  Gerrits, C J H ^a   Creemers, G J ^a   Schellens, J H M ^a   Wissel, P ^b   Planting, A S Th ^a   Kunka, R ^b   Selinger, K ^b   De Boer Dennert, M ^a   Marijnen, Y ^c   Harteveld, M ^a   Verweij, J ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b GLAXOSMITHKLINE   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

GI147211; Phase I study; Topoisomerase 1

Indexed keywords

ANTIEMETIC AGENT; CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE; LURTOTECAN; UNCLASSIFIED DRUG;

ADULT; AGED; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MALE; MAXIMUM PERMISSIBLE DOSE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PLASMA CLEARANCE; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS;

EID: 0029928849     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.130     Document Type: Article

References (27)

1. BURRIS HA, HANAUSKE AR, JOHNSON RK, MASHALL MH, KUHN JG, HILSENBEEK SG AND VON HOFF DD. (1992). Activity of topotecan a new topoisomerase I inhibitor, against human colony-forming units in vitro. J. Natl Cancer Inst., 84, 1816-1820.
2. CREAVEN PJ, ALLEN LM AND MUGGIA FM. (1972). Plasma camptothecin (NSC 100880) levels during a 5-days course of treatment: relation to dose and toxicity. Cancer Chem. Rep., 56, 573-578.
3. CREEMERS GJ, LUND B AND VERWEIJ J. (1994). Topoisomerase I inhibitors: Topotecan and irinotecan. Cancer Treat. Rev., 20, 73-96.
4. COVEY JM, JAXEL C AND KOHN KW. (1989). Protein-link DNA strand break induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res., 49, 5016-5022.
5. D'ARPA P AND LIU LF. (1989). Topoisomerase-targeting antitumor drugs. Biochim. Biophys. Acta, 989, 163-177.
6. EISENHAUER EA, WAINMAN N, BOOS G, MACDONALD D, BRAMWELL V AND NCI CANADA CLINICAL TRIALS GROUP. (1994). Phase II trials of topotecan in patients(pts) with malignant glioma and soft tissue sarcoma. Proc. Am. Assoc. Clin. Onc., 13, 488.
7. EMERSON DL, VUONG A, MCINTYRE MS, CROOM DK AND BESTERMAN JM. (1993). In vivo efficacy of two new water-soluble camptothecin analogs in the human cancer xenograft model. Proc. Am. Assoc. Cancer Res., 34, 419.
8. EMERSON DL, MCINTYRE G, LUZZIO MJ AND WISSEL PS. (1994). Preclinical antitumor activity of a novel water-soluble camptothecin analog (GI147211C). Ann. Oncol., 5, (suppl. 5), 185.
9. EMERSON DL, BESTERMAN JM, BROWN HR, EVANS MG, LEITNER PP, LUZZIO MJ, SCHAFFER JE, STERNBACH DD, UEHLING D AND VUONG A. (1995). In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues. Cancer Res., 55, 603-609.
10. ENG WK, FAUCETTE L, JOHNSON RK AND STERNGHANZ R. (1988). Evidence that topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol. Pharmacol., 34, 755-760.
11. GIOVANELLA BC, STEHLIN JS, WALL ME, WANI MC, NICHOLAS AW, LIU FL, SILBER R AND POTMESIL M. (1989). DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science, 246, 1046-1048.
12. GOTTLIEB JA, GUARINO AM, CALL JB, OLIVERIO VT AND BLOCK JB. (1970). Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880). Cancer Chem. Rep., 54, 461-470.
13. HIRABAYASHI N, KIM R, NISHIYAMA M, AOGI K, SAEKI S, TOGE T AND OKADA K. (1992). Tissue expression of topoisomerase I and II in digestive tract cancers and adjacent normal tissues. Proc. Am. Assoc. Cancer Res., 33, 2603.
14. HOCHSTER H, LIEBES L, SPEYER J, SORICH J, TAUBES B, ORATZ R, WERN EJ, CHACHOUA A, RAPHAEL B, VINCI RE AND BLIM RH. (1994). Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J. Clin. Oncol., 12, 553-559.
15. HORWITZ SP AND HORWITZ HS. (1973). Effects of camptothecin on the breakage and repair of DNA during the cell cycle. Cancer Res., 33, 2834-2836.
16. HOUGHTON PJ, CHESHIRE PJ, HALLMAN JC, BISSERY MC, MATHIEU-BOUÉ A AND HOUGHTON J. (1993). Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4[1-piperidino]-1-piperidino)-carbonyloxycamptothecin against human tumor xenografts: lack of cross-resistance in vivo tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethy-lamino-methyl-10-camptothecin. Cancer Res., 53, 2823-2829.
17. HSIANG YH AND LIU LF. (1988). Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res., 48, 1722-1726.
18. HSIANG YH, HERTZBERG R, HECHT S AND LIU LF. (1985). Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem., 260, 14873-14878.
19. MUGGIA FM, CREAVEN PJ, HANSEN HH, COHEN MH AND SELANRING OS. (1972). Phase I clinical trial of weekly and daily treatment with camptothecin (NSC 100880): correlation with preclinical studies. Cancer Chem. Rep., 56, 515-521.
20. NATIONAL CANCER INSTITUTE. (1988). Guidelines for Reporting of Adverse Drug Reactions. Division of Cancer Treatment, National Cancer Institute: Bethesda, MD.
21. POTMESIL M. (1994). Camptothecins: from bench research to hospital wards. Cancer Res., 54, 1431-1439.
22. POTMESIL M, HSIANG YH, LIU LF, BANK B, GROSSBERG H, KIRSCHENBAUM S, FORLENZAR TJ, RENZINCH A, KANGANIS D, KNOWLES D, TRAGANOS F AND SILBER R (1988). Resistance of human leukemia and normal lymphocytes to drug induced DNA cleavage and low levels of topoisomerase II. Cancer Res., 48, 3537-3543.
23. ROWINSKY EK, GROCHOW LB, HENDRICKS CB, ETTINGER DS, FORASTIERE AA, HUROWITZ LA, MCGUIRE WP, SATORIUS SE, LUBEJKO BG, KAUFMANN SH AND DONEHOWER RC. (1992). Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J. Clin. Oncol., 10, 647-656.
24. SLICHENMYER WJ, ROWINSKY EK, DONEHOWER RCAND KAUFMANN SH. (1993). The current status of camptothecin analogues as antitumor agents. J. Natl Cancer Inst., 85, 271-291.
25. STAFFORD CG AND ST. CLAIRE III RL. (1995). High-performance liquid chromatographic analysis of the lactone and carboxylate forms of a topoisomerase I inhibitor (the antitumor drug GI147211) in plasma. J. Chromatogr., 663, 119-126.
26. VERWEIJ J, LUND B, BEIJNEN J, PLANTING A, DE BOER-DENNERT M, KOIER I, ROSING H AND HANSSEN H. (1993). Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Ann. Oncol., 4, 673-678.
27. WORLD HEALTH ORGANIZATION. (1979). WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publication No. 40. World Health Organization: Geneva, Switzerland.